Biocardia Company Insiders

BCDA Stock  USD 1.23  0.04  3.15%   
Biocardia's insiders are aggressively buying. The analysis of the overall insider sentiment regarding Biocardia suggests that vertually all insiders are extremely bullish. Biocardia employs about 17 people. The company is managed by 7 executives with a total tenure of roughly 18 years, averaging almost 2.0 years of service per executive, having 2.43 employees per reported executive.
Peter Altman  CEO
President CEO, Principal Executive Officer, Director
David McClung  President
Principal Financial and Accounting Officer, Vice President - Finance

Insider Sentiment 100

 Aggressively Buying

 
Selling
 
Buying

Latest Trades

2025-09-19Andrew Scott BlankAcquired 288000 @ 1.25View
2025-08-22Peter AltmanAcquired 700 @ 1.83View
2025-08-13Peter AltmanAcquired 100 @ 1.83View
2025-08-12Peter AltmanAcquired 400 @ 1.75View
2025-08-11Peter AltmanAcquired 1700 @ 1.76View
2025-06-30Simon H StertzerAcquired 72289 @ 2.08View
2025-05-30Peter AltmanAcquired 100 @ 2.21View
2025-05-22Peter AltmanAcquired 700 @ 1.89View
2025-05-20Peter AltmanAcquired 1600 @ 2.08View
2025-05-16Peter AltmanAcquired 300 @ 2.43View
2025-05-14Peter AltmanAcquired 100 @ 2.99View
2025-04-23Peter AltmanAcquired 26246 @ 1.91View
2025-04-15Peter AltmanAcquired 100 @ 2.14View
2025-04-10Peter AltmanAcquired 300 @ 1.99View
Monitoring Biocardia's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biocardia. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in small area income & poverty estimates.
For information on how to trade Biocardia Stock refer to our How to Trade Biocardia Stock guide.

Biocardia Management Team Effectiveness

The company has return on total asset (ROA) of (0.8645) % which means that it has lost $0.8645 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.1747) %, meaning that it created substantial loss on money invested by shareholders. Biocardia's management efficiency ratios could be used to measure how well Biocardia manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -2.03. The current year's Return On Capital Employed is expected to grow to -5.42. At present, Biocardia's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 235.3 K, whereas Total Assets are forecasted to decline to about 3.5 M.
The current year's Common Stock Shares Outstanding is expected to grow to about 2.9 M, whereas Net Loss is forecasted to decline to (11.3 M).

Biocardia Workforce Comparison

Biocardia is rated fourth in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 149. Biocardia retains roughly 17.0 in number of employees claiming about 11% of equities under Health Care industry.

Biocardia Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Biocardia insiders, such as employees or executives, is commonly permitted as long as it does not rely on Biocardia's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Biocardia insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Biocardia Notable Stakeholders

A Biocardia stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Biocardia often face trade-offs trying to please all of them. Biocardia's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Biocardia's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Peter AltmanPresident CEO, Principal Executive Officer, DirectorProfile
David McClungPrincipal Financial and Accounting Officer, Vice President - FinanceProfile
Edward GillisSenior DevicesProfile
Ian McNieceChief OfficerProfile
Sujith ShettyChief RegulatoryProfile
Sujith MBBSChief RegulatoryProfile
Miranda BenvenutiInvestor ExecutiveProfile

About Biocardia Management Performance

The success or failure of an entity such as Biocardia often depends on how effective the management is. Biocardia management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Biocardia management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Biocardia management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(2.13)(2.03)
Return On Capital Employed(5.70)(5.42)
Return On Assets(2.13)(2.03)
Return On Equity(9.49)(9.02)
Please note, the presentation of Biocardia's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Biocardia's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Biocardia's management manipulating its earnings.

Biocardia Workforce Analysis

Traditionally, organizations such as Biocardia use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Biocardia within its industry.

Biocardia Manpower Efficiency

Return on Biocardia Manpower

Revenue Per Employee3.4K
Revenue Per Executive8.3K
Net Loss Per Employee467.4K
Net Loss Per Executive1.1M
Working Capital Per Employee17.7K
Working Capital Per Executive43K

Complementary Tools for Biocardia Stock analysis

When running Biocardia's price analysis, check to measure Biocardia's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biocardia is operating at the current time. Most of Biocardia's value examination focuses on studying past and present price action to predict the probability of Biocardia's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biocardia's price. Additionally, you may evaluate how the addition of Biocardia to your portfolios can decrease your overall portfolio volatility.
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
AI Portfolio Prophet
Use AI to generate optimal portfolios and find profitable investment opportunities
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges